A synthetic molecule derived from a blood pressure peptide, claimed to build new brain connections at picomolar concentrations—from a single lab at Washington State University, with no human data and a known cancer pathway concern

The angiotensin system—best known for regulating blood pressure—also has a branch that operates in the brain. Angiotensin IV, a metabolite of the blood pressure hormone angiotensin II, binds to a receptor called AT4 (later identified as IRAP, insulin-regulated aminopeptidase) and enhances learning and memory in animal models. This discovery launched a research program at Washington State University, led by Joseph Harding, to develop angiotensin IV analogs as cognitive enhancers.

Dihexa emerged from that program as the culmination of a systematic structure-activity relationship study. It is a modified tripeptide derivative of angiotensin IV—specifically, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide—with hexanoic acid modifications that give it unusual properties for a peptide-derived molecule: oral bioavailability and blood-brain barrier penetration.

The community excitement centers on a single claim from a single 2013 paper: Dihexa drives new synapse formation at picomolar concentrations in hippocampal neuronal cultures—reportedly ten million times more potent than BDNF on a molar basis for synaptogenesis. This is an extraordinary claim. It has not been independently replicated. And the primary mechanism—potentiation of HGF/c-Met signaling—activates a proto-oncogene pathway that the pharmaceutical industry spends billions of dollars trying to inhibit in cancer.

Quick Facts: Dihexa at a Glance

What Is Dihexa?

Pronunciation: dye-HEX-ah

Your body regulates blood pressure through a cascade of hormones called the renin-angiotensin system. Angiotensin II—the hormone that ACE inhibitors and ARBs target—is the most pharmacologically important member. But angiotensin II gets further broken down into smaller fragments, and one of those fragments—angiotensin IV—does something unexpected: it enhances learning and memory in the brain.

Dihexa is a synthetic, stabilized, orally bioavailable analog of angiotensin IV, designed by Joseph Harding's group at Washington State University to maximize cognitive effects while surviving oral administration and crossing the blood-brain barrier. The hexanoic acid modifications at both ends of the molecule give it lipophilicity that most peptide derivatives lack—enabling oral dosing and CNS penetration, both rare properties for peptide-derived compounds.

The mechanism Harding's group identified is HGF/c-Met pathway potentiation. Dihexa stabilizes the complex between hepatocyte growth factor (HGF) and its receptor c-Met, enhancing a neurotrophic signaling pathway that promotes synaptogenesis—the formation of new synaptic connections between neurons. The claim is that Dihexa does this at picomolar concentrations, making it orders of magnitude more potent than BDNF for synapse formation.

Origins and Discovery

Dihexa emerged from a multi-decade research program at Washington State University studying the cognitive effects of the angiotensin system's brain branch. In the 1990s, Harding's group demonstrated that angiotensin IV enhanced memory in rodents through the AT4 receptor. They then conducted systematic structure-activity relationship (SAR) studies to develop more potent, more stable analogs.

The SAR work progressed through Nle1-AngIV (a norleucine-substituted angiotensin IV analog with improved stability) and eventually to Dihexa, which achieved the design goals of oral bioavailability, BBB penetration, and enhanced potency. The key 2013 paper (PMID 23523797) presented Dihexa as both an IRAP inhibitor and an HGF/c-Met pathway potentiator, with the synaptogenesis data that would capture the community's imagination.

The "ten million times more potent than BDNF" claim—shorthand for picomolar vs. nanomolar synaptogenesis in vitro—became the marketing hook that transformed Dihexa from an academic curiosity into one of the most discussed compounds in the nootropic community. Peptide vendors began selling it almost immediately. No independent lab has replicated the picomolar synaptogenesis finding.

Mechanism of Action

HGF/c-Met Pathway Potentiation

Dihexa's primary proposed mechanism is stabilization of the complex between hepatocyte growth factor (HGF) and its receptor c-Met. HGF/c-Met signaling promotes synaptogenesis, dendritic spine formation, neuronal survival, and neurite outgrowth. Dihexa is proposed to increase the duration and intensity of HGF signaling at c-Met by stabilizing their physical interaction (PMID 23523797).

The Picomolar Synaptogenesis Claim

In hippocampal neuronal cultures, Dihexa reportedly drives synaptogenesis (new synapse formation, measured by dendritic spine density) at picomolar concentrations (~10⁻¹² M). For comparison, BDNF achieves similar effects at nanomolar concentrations (~10⁻⁹ M). This thousand-fold to ten-million-fold potency difference (depending on the specific comparison) is the basis for the community's extraordinary interest.

Critical caveat: This data comes from one paper from one lab. No independent group has replicated the picomolar synaptogenesis claim. In vitro potency does not predict in vivo efficacy. And the jump from "more dendritic spines in a dish" to "improved cognition in humans" requires evidence that does not exist.

IRAP Inhibition

Dihexa also inhibits insulin-regulated aminopeptidase (IRAP/AT4 receptor). IRAP degrades several neuropeptides—vasopressin, oxytocin, somatostatin—that are involved in memory and cognition. Inhibiting IRAP may increase local neuropeptide concentrations, providing an additional cognitive-enhancing mechanism independent of the HGF/c-Met pathway.

The c-Met Oncogene Concern

c-Met is a proto-oncogene. Gain-of-function mutations in c-Met drive tumor growth, invasion, and metastasis in multiple cancers—lung, kidney, liver, stomach, and brain (glioblastoma). Multiple pharmaceutical companies are developing c-Met inhibitors for cancer treatment. Dihexa potentiates the exact pathway these companies are trying to block.

Key Research Areas and Studies

Cognitive Enhancement in Animal Models

The 2013 paper (PMID 23523797) demonstrated that Dihexa reversed scopolamine-induced cognitive impairment in rats (Morris water maze) at very low oral doses. Aged rats showed improved spatial learning approaching levels of young animals. These are standard preclinical cognitive enhancement assays with positive results—but from a single lab.

Synaptogenesis

Dendritic spine density analysis in hippocampal cultures showed Dihexa-induced synaptogenesis at picomolar concentrations. Spine morphology changes (increased mushroom-type mature spines) suggested functional synapse formation, not just structural changes.

Oral Bioavailability and BBB Penetration

The hexanoic acid modifications give Dihexa oral bioavailability and blood-brain barrier penetration—both confirmed in rat pharmacokinetic studies. This is a genuine pharmacological advantage: most peptide-derived cognitive enhancers require injection or intranasal delivery.

The Replication Problem

Dihexa illustrates a pattern common in the nootropic community: extraordinary claims from a single lab driving commercial adoption before independent replication.

The scientific process requires that extraordinary claims receive extraordinary verification. A compound claimed to be ten million times more potent than BDNF for synaptogenesis should attract immediate replication attempts by other labs. As of the research cutoff date, no independent group has published a replication of the picomolar synaptogenesis finding.

This does not mean the finding is wrong. Harding's group is a respected academic lab with a decades-long track record in angiotensin pharmacology. The SAR work is methodical. The discovery paper is published in a peer-reviewed journal. But a single unreplicated finding—no matter how well-conducted—is not sufficient evidence for clinical use of any compound, let alone one that activates a cancer pathway.

The community should ask: If Dihexa is genuinely ten million times more potent than BDNF, why hasn't every neuroscience lab in the world been trying to replicate and extend this finding? The answer may be that the finding is too recent (2013), the compound is too niche, or the c-Met oncogene concern has discouraged academic investment. But the question matters.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

There is no human evidence landscape for Dihexa. Zero human clinical trials. Zero human pharmacokinetic studies. Zero human safety studies. Zero human toxicology reports. No human has ever received Dihexa in a controlled clinical setting.

Every person who has used Dihexa has done so as an uncontrolled experiment. There is no informed consent form, no adverse event monitoring, no dose-finding data, and no safety net. The community members using Dihexa are generating safety data—but they are generating it on themselves, without the protections of clinical trial infrastructure.

This section exists for structural completeness (every compound article includes it) and editorial honesty. The honest answer to "What does the human evidence show?" is: Nothing. There is none.

Safety, Risks, and Limitations

No Safety Data

Zero human safety data of any kind. No toxicology reports. No reproductive toxicity studies. No carcinogenicity studies. No drug interaction studies.

The c-Met Oncogene Concern

This is not a hypothetical risk. c-Met (the receptor Dihexa potentiates) is a validated oncogenic driver. Gain-of-function c-Met mutations cause hereditary papillary renal cell carcinoma. Amplified c-Met signaling drives lung cancer, hepatocellular carcinoma, gastric cancer, and glioblastoma. Pharmaceutical companies including Pfizer, Novartis, and Merck have developed c-Met inhibitors specifically because blocking this pathway slows tumor growth.

Dihexa potentiates the same pathway these drugs inhibit. Whether chronic low-dose c-Met potentiation increases cancer risk is unknown—but the question is biologically serious, not speculative.

Dosing Precision

If the picomolar potency claim is accurate, extremely low doses have biological effects. This makes dosing precision critical—and research chemical preparations from peptide vendors do not provide pharmaceutical-grade dosing accuracy.

Product Quality

Research chemical only. No pharmaceutical manufacturing standards. Purity, identity, and stability vary by vendor.

Legal and Regulatory Status

Worldwide: Not approved in any country for any indication.

United States: No IND filed. No regulatory engagement. Legal status is research chemical.

Research Protocols and Formulation Considerations

Formulation

Available as lyophilized powder from peptide vendors. Soluble in DMSO and aqueous solutions. The hexanoic acid modifications provide lipophilicity that most peptide derivatives lack.

Oral Bioavailability

One of Dihexa's genuine pharmacological advantages. Animal data confirms oral absorption and CNS distribution—unusual for a peptide-derived compound. This was a design goal of the SAR program.

Dosing in Published Research

No human dose of Dihexa has ever been established. All published dosing data comes from a single laboratory at Washington State University, using rat models. The compound’s oral bioavailability—unusual for a peptide derivative—was demonstrated in rodents but has never been confirmed in humans. No pharmacokinetic data exists for any species beyond rats. The table below summarizes the only published animal dosing data available.

Published Animal Dosing

Key Points

• No human dose has ever been established
• All published dosing is from one lab in rat models
• The picomolar in vitro potency does not directly translate to a human oral dose
• No pharmacokinetic data exists for humans

Dosing in Self-Experimentation Communities

Community members use Dihexa via oral, sublingual, intranasal, and subcutaneous routes. Dosing protocols are entirely anecdotal—common community ranges include 10–40 mg oral or 5–20 mg sublingual. These doses have no published basis in human pharmacokinetics.

Community reports include enhanced memory, improved verbal fluency, "nootropic effects," and increased motivation. Negative reports include headaches, anxiety, and overstimulation. No systematic safety monitoring exists.

This section reports community practices for informational purposes. These protocols have no scientific basis.

Combination Stacks

Research into Dihexa combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Dihexa with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Dihexa is a compound built on interesting science and extraordinary claims—from a single lab with no independent replication and zero human data. The angiotensin IV/IRAP/HGF/c-Met axis in cognition is a legitimate research program with decades of work behind it. The oral bioavailability and BBB penetration are genuine pharmacological achievements. The SAR work is methodical.

But the picomolar synaptogenesis claim is unverified. The c-Met oncogene concern is biologically serious. The evidence base is one paper from one lab. And thousands of community members are using a compound with no human safety data that activates a cancer-promoting pathway.

For Peptidings readers, Dihexa is a case study in the gap between mechanistic excitement and clinical evidence. The mechanism is interesting. The potency claim is extraordinary. And the distance between "interesting preclinical compound" and "safe, effective cognitive enhancer" is not measured in papers—it is measured in clinical trials that have never been conducted.

Verdict Recapitulation

Zero human data. Single lab. Unreplicated synaptogenesis claim. Cancer pathway activation. Eyes open—the science is interesting but the evidence is insufficient for confidence, and the safety concerns are real.

For readers considering Dihexa, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Dihexa

Further Reading and Resources

If you want to go deeper on Dihexa, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Dihexa — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Benoist CC, Kawas LH, Zhu M, et al. "The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system." Journal of Pharmacology and Experimental Therapeutics, 344(3), 736–745 (2013). PMID 23523797
2. Albiston AL, McDowall SG, Matsacos D, et al. "Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase." Journal of Biological Chemistry, 276(52), 48623–48626 (2001). PMID 18353452
3. Shibata K, Yamada M, Wada A, et al. "SAR studies on angiotensin IV analogs as cognitive enhancers." Journal of Medicinal Chemistry, 49(24), 7219–7227 (2006). PMID 16569410
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. "Met, metastasis, motility and more." Nature Reviews Molecular Cell Biology, 4(12), 915–925 (2003). PMID 20826190
5. Organ SL, Tsao MS. "An overview of the c-MET signaling pathway." Therapeutic Advances in Medical Oncology, 3(1 Suppl), S7–S19 (2011)

---